Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

A Sixteen-Week, Multi-Center, Open-Label Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone In Subjects Diagnosed With Schizophrenia Or Schizoaffective Disorder

The primary objective of this study is to evaluate change in weight as a result of switching from quetiapine to ziprasidone, in subjects with schizophrenia or schizoaffective disorder who have failed to achieve a satisfactory clinical response to quetiapine due to lack of efficacy or poor tolerability.

Study Overview

• Status: Completed
• Conditions: Schizophrenia; Schizoaffective Disorder
• Intervention / Treatment: Drug: ziprasidone

• Study Type: Interventional
• Enrollment (Actual): 255
• Phase: Phase 4

Contacts and Locations

Study Locations

• Brazil
  • GO
    • Aparecida de Goiânia, GO, Brazil, 74922-810
      • Pfizer Investigational Site
  • RJ
    • Rio de Janeiro, RJ, Brazil, 22290-140
      • Pfizer Investigational Site
  • SP
    • São Paulo, SP, Brazil, 05403-010
      • Pfizer Investigational Site
• Germany
  • Berlin, Germany, 10117
    • Pfizer Investigational Site
  • Duesseldorf, Germany, 40629
    • Pfizer Investigational Site
  • Hamburg, Germany, 20246
    • Pfizer Investigational Site
  • Muenchen, Germany, 80336
    • Pfizer Investigational Site
• Greece
  • Athens, Greece, 10676
    • Pfizer Investigational Site
  • Thessaloniki, Greece, 546 42
    • Pfizer Investigational Site
• Spain
  • Zamora, Spain, 49021
    • Pfizer Investigational Site
• Turkey
  • Ankara, Turkey, 06200
    • Pfizer Investigational Site
  • Izmit, Turkey, 41380
    • Pfizer Investigational Site
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85028
      • Pfizer Investigational Site
  • California
    • Costa Mesa, California, United States, 92626
      • Pfizer Investigational Site
    • Garden Grove, California, United States, 92845
      • Pfizer Investigational Site
    • National City, California, United States, 91950
      • Pfizer Investigational Site
    • Orange, California, United States, 92868-8040
      • Pfizer Investigational Site
    • San Diego, California, United States, 92123
      • Pfizer Investigational Site
    • Temecula, California, United States, 92591
      • Pfizer Investigational Site
    • Torrance, California, United States, 90505
      • Pfizer Investigational Site
  • Florida
    • Hialeah, Florida, United States, 33016
      • Pfizer Investigational Site
    • Miami, Florida, United States, 33126
      • Pfizer Investigational Site
    • Miami, Florida, United States, 33143
      • Pfizer Investigational Site
  • Illinois
    • Chicago, Illinois, United States, 60640
      • Pfizer Investigational Site
    • Des Plaines, Illinois, United States, 60016
      • Pfizer Investigational Site
    • Oakbrook Terrace, Illinois, United States, 60181
      • Pfizer Investigational Site
    • Schaumburg, Illinois, United States, 60194
      • Pfizer Investigational Site
  • Kansas
    • Topeka, Kansas, United States, 66606
      • Pfizer Investigational Site
  • Mississippi
    • Olive Branch, Mississippi, United States, 38654
      • Pfizer Investigational Site
  • Missouri
    • Saint Louis, Missouri, United States, 63368
      • Pfizer Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89102
      • Pfizer Investigational Site
  • New Hampshire
    • Nashua, New Hampshire, United States, 03060
      • Pfizer Investigational Site
  • New York
    • Olean, New York, United States, 14760
      • Pfizer Investigational Site
    • Staten Island, New York, United States, 10312
      • Pfizer Investigational Site
  • Tennessee
    • Memphis, Tennessee, United States, 38133
      • Pfizer Investigational Site
    • Memphis, Tennessee, United States, 38117
      • Pfizer Investigational Site
  • Texas
    • Dallas, Texas, United States, 75231
      • Pfizer Investigational Site
    • DeSoto, Texas, United States, 75115
      • Pfizer Investigational Site
  • Washington
    • Bothell, Washington, United States, 98011
      • Pfizer Investigational Site
    • Kirkland, Washington, United States, 98033
      • Pfizer Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males or females, between 18 and 55 years of age, at the time of consent.
• Subjects must have a primary diagnosis of schizophrenia, any subtype (code 295.xx), or schizoaffective disorder as defined in DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition)
• Subjects must have normal vital signs, physical examination, ECG, and laboratory findings except for minor deviations determined and documented to be clinically insignificant by the investigator or a sub-investigator who is a medical doctor.

Exclusion Criteria:

• Subjects who are unable to provide informed consent
• Subjects who meet criteria for a DSM-IV-TR Axis I (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition) diagnosis other than schizophrenia or schizoaffective disorder, including psychoactive substance abuse or dependence within one year of study entry
• Females who are pregnant, breast feeding, or lactating at screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: A1; atypical antipsychotic for the treatment of schizophrenia	Drug: ziprasidone; Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase; Other Names: Geodon, Zeldox

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Weight at Week 16	Weight value: Change = value at Week 16 or Week 16 Last Observation Carried Forward (LOCF) minus value at Baseline.	Baseline, Week 16, Week 16 LOCF

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Fasting Lipid Profile (Total Cholesterol) at Week 16	Total cholesterol value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Change From Baseline in High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), and Triglycerides at Week 16	HDL, LDL, and triglyceride value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 16	HbAlc value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Change From Baseline in Fasting Glucose at Week 16	Fasting glucose value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Change From Baseline in Fasting Insulin at Week 16	Fasting insulin value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Change From Baseline in Waist and Hip Circumference at Week 16	Waist and hip circumference value: Change = value at Week 16 minus value at Baseline.	Baseline, Week 16
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score, Global Severity Score, and Global Incapacitation Score at Week 16	AIMS: a 12-item clinician administered instrument assessing observed abnormal movements in different parts of body. Ten items scored on a 5-point scale (0 = none/normal, 4 = severe) evaluate abnormal movements in three main anatomic areas (orofacial area, extremities, and trunk). Two items are yes/no questions regarding dentures. Total scores range from 0 to 42. Item 8 indicates severity, item 9 indicates Incapacitation. AIMS total, global severity, or global incapacitation score: Change = score at Week 16 minus score at Baseline.	Baseline, Week 16
Change From Baseline in Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score, and Positive and Negative Subscale Scores at Week 16	PANSS measures severity of psychopathology in subjects with schizophrenia, schizoaffective disorder and other psychotic disorders. It includes 3 scales and a total of 30 items: 7 items comprise the positive scale, 7 comprise the negative scale, and 16 items measure general psychopathology. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210. PANSS total score and positive and negative scores: Change = score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Change From Baseline in Clinical Global Impression Severity Scale (CGI-S) at Week 16	The CGI-S is a single item, clinician-rated scale that assesses the global severity of the subject's overall illness. The CGI-S ratings range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). CGI-S score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Observed Cases of Clinical Global Impression Improvement Scale (CGI-I) Scores at Week 16	The CGI-I is a 7-point, single-item, clinician-rated scale that assesses global improvement in the subject's clinical state in response to study treatment, and as compared to their status at pre-treatment baseline. Possible CGI-I scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse).	Week 16, Week 16 LOCF
Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Total Score at Week 16	The CDSS is a 9-item, clinician-rated scale validated for rating the severity of depressive symptoms in subjects diagnosed with schizophrenia, and independent of confounding negative and extrapyramidal symptoms. The CDSS rates the severity of depressive symptoms on a 4-point scale ranging from 0 (absent) to 3 (severe). The CDSS depression total score is obtained by adding each of the item scores. Total possible score ranges from 0 to 27. CDSS possible total score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Change From Baseline in Schizophrenia Cognition Rating Scale (SCoRS) Total Score and Global Rating at Week 16	The SCoRS is a 20-question rating scale completed via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. Each question was completed using a 4-point scale (ranging from 1=none to 4=severe). Total possible score ranged from 20 to 80. At the end of the 20 questions, the interviewer completed a Global Scale of 1-10, rating subject's overall difficulty. Higher scores on both indicated greater cognitive impairment. SCoRS total score and global rating: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Change From Baseline in Global Assessment of Function Scale (GAF) Score at Week 16	GAF Scale measures the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale. Total possible score ranges from 0 (not enough information available to provide GAF) to 100 (Superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many qualities. No symptoms). The assessment was done by a trained assessor. GAF scale score: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF
Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TQSM) Effectiveness, Side Effect, Convenience, and Global Satisfaction Subscales at Week 16	The TSQM is a 13-item subject-rated scale that evaluates the effectiveness, side effects and convenience of the medication over the past 2-3 weeks. Likert scale: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7=Extremely Satisfied. Worst value is 0 and best value is 100. TSQM Effectivenss, Side Effect, Convenience, and Global Satisfaction scores: Change: score at Week 16 or Week 16 LOCF minus score at Baseline.	Baseline, Week 16, Week 16 LOCF

Collaborators and Investigators

• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start: November 1, 2006
• Primary Completion (Actual): December 1, 2008
• Study Completion (Actual): March 1, 2009

Study Registration Dates

• First Submitted: November 29, 2006
• First Submitted That Met QC Criteria: November 29, 2006
• First Posted (Estimate): December 4, 2006

Study Record Updates

• Last Update Posted (Actual): March 29, 2021
• Last Update Submitted That Met QC Criteria: March 1, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: ziprasidone, quetiapine (Seroquel) switch, open label, flexible dose, schizophrenia, schizoaffective disorder
• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia; Psychotic Disorders; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Antipsychotic Agents; Tranquilizing Agents; Psychotropic Drugs; Serotonin Agents; Dopamine Agents; Serotonin Antagonists; Dopamine Antagonists; Ziprasidone
• Other Study ID Numbers: A1281148